Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 645-649

  McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Asenapine; Bipolar disorder; Manic; Mixed state; Pharmacology

Indexed keywords

AMPA RECEPTOR; ANTIDEPRESSANT AGENT; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; SEROTONIN 2A RECEPTOR;

ADULT; BIPOLAR DISORDER; BIPOLAR I DISORDER; BODY COMPOSITION; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPESTHESIA; MAJOR DEPRESSION; MANIA; METABOLIC PARAMETERS; MIXED MANIA AND DEPRESSION; PATIENT COMPLIANCE; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING;

ADMINISTRATION, SUBLINGUAL; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG EVALUATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PUBMED;

EID: 77951798728     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.49     Document Type: Review

References (18)

1. McIntyre RS, Konarski JJ. Tolerability profles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry 66 (Suppl. 3), 28-36 (2005). (Pubitemid 40461409)
2. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 11 (6), 559-595 (2009).
3. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebocontrolled trials. J. Clin. Psychiatry 67 (4), 509-516 (2006). (Pubitemid 43764227)
4. Tohen M, Bowden CL, Calabrese JR et al. Infuence of sub-syndromal symptoms after remission from manic or mixed episodes. Br. J. Psychiatry 189, 515-519 (2006). (Pubitemid 44876870)
5. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry 163 (2), 217-224 (2006).
6. Newcomer JW, Nasrallah HA, Loebel AA. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol. 24 (5 Suppl. 1), S1-S6 (2004).
7. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 11 (7), 673-686 (2009).
8. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 11 (8), 815-826 (2009).
9. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J. Affect. Disord. 122 (1-2), 27-38 (2010).
10. Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr. Dis. Treat. 5, 483-490 (2009).
11. Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 63 (5), 413-420 (2009).
12. Marston HM, Young JW, Martin FD et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl.) 206 (4), 699-714 (2009).
13. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl.) 198 (1), 103-111 (2008).
14. Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TT. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl.) 204 (2), 251-264 (2009).
15. 2 receptors in the rat brain. Eur. Neuropsychopharmacol. 19 (3), 177-187 (2009).
16. Choi YK, Wong EH, Henry B, Shahid M, Tarazi FF. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int. J. Neuropsychopharmacol. 19, 1-6 (2009).
17. Belmaker RR. Patient history must be incorporated into any guidelines. Bipolar Disord. 11 (7), 772 (2009).
18. Frye MA, Ketter TA, Leverich GS et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry 61 (1), 9-15 (2000).